Document is current
Any future updates will be listed below
-
Authors
Jomard, Anne https://orcid.org/0000-0002-9733-7958
Liberale, Luca https://orcid.org/0000-0003-1472-7975
Doytcheva, Petia
Reiner, Martin F. https://orcid.org/0000-0002-9887-2469
Müller, Daniel https://orcid.org/0000-0002-4674-4019
Visentin, Michele https://orcid.org/0000-0002-0209-5600
Bueter, Marco
Lüscher, Thomas F.
Vettor, Roberto
Lutz, Thomas A. https://orcid.org/0000-0002-5056-8548
Camici, Giovanni G. https://orcid.org/0000-0002-0523-0695
Osto, Elena https://orcid.org/0000-0001-8196-5696
-
Funding
Funding for this research was provided by:
Schweizerische Herzstiftung
Heubergstiftung
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_197510, 310030_197510, PRIMA: PR00P3_179861 / 1)
Alfred and Annemarie von Sick Grants for Translational and Clinical Research Cardiology and Oncology
Swiss Life Foundation
- License Information
-
More Information
Article History
Received: 31 January 2022
Accepted: 13 May 2022
First Online: 23 May 2022
Competing interests
: GGC and LL are co-inventors on the International Patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies, which specifically bind IL‐1α to reduce various sequelae of ischaemia‐reperfusion injury to the central nervous system. GGC is a consultant to Sovida solutions limited. All other Authors declare no conflict of interest.
